Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic
-Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
-Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in…
Archives Press release 2022
Archives Press release 2022